The world's scientific and social network for malaria professionals
Subscribe to free Newsletter | 10316 malaria professionals are enjoying the free benefits of MalariaWorld today

antimalarials

A Single-Dose Combination Study with the Experimental Antimalarials Artefenomel and DSM265 To Determine Safety and Antimalarial Activity against Blood-Stage Plasmodium falciparum in Healthy Volunteers

December 23, 2019 - 16:04 -- Open Access
Author(s): 
McCarthy JS, Rückle T, Elliott SL, Ballard E, Collins KA, Marquart L, Griffin P, Chalon S, Möhrle JJ
Reference: 
Antimicrob Agents Chemother. 2019 Dec 20;64(1). pii: e01371-19.

Artefenomel and DSM265 are two new compounds that have been shown to be well tolerated and effective when administered as monotherapy malaria treatment. This study aimed to determine the safety, pharmacokinetics, and pharmacodynamics of artefenomel and DSM265 administered in combination to healthy subjects in a volunteer infection study using the Plasmodium falciparum-induced blood-stage malaria model. Thirteen subjects were inoculated with parasite-infected erythrocytes on day 0 and received a single oral dose of artefenomel and DSM265 on day 7.

NOT Open Access | 6-Hydrophobic aromatic substituent pyrimethamine analogues as potential antimalarials for pyrimethamine-resistant Plasmodium falciparum

December 16, 2019 - 16:55 -- NOT Open Access
Author(s): 
Saepua S, Sadorn K, Vanichtanankul J, Anukunwithaya T, Rattanajak R, Vitsupakorn D, Kamchonwongpaisan S, Yuthavong Y, Thongpanchang C
Reference: 
Bioorganic & Medicinal Chemistry Volume 27, Issue 24, 15 December 2019, 115158

The series of des-Cl (unsubstituted) and m-Cl phenyl analogues of PYR with various flexible 6-substituents were synthesized and studied for the binding affinities with highly resistant quadruple mutant (QM) DHFR. The derivatives carrying 4 atoms linker with a terminal carboxyl substituted on the aromatic ring exhibited good inhibition to the QM enzyme and also showed effective antimalarial activities against resistant P. falciparum bearing the mutant enzymes with relatively low cytotoxicity to mammalian cells.

NOT Open Access |Recent advances in transmission-blocking drugs for malaria elimination

December 2, 2019 - 15:10 -- NOT Open Access
Author(s): 
Wadi I, Nath M, Anvikar AR, Singh P, Sinha A.
Reference: 
Future Med Chem. 2019 Nov 29.

The scientific community worldwide has realized that malaria elimination will not be possible without development of safe and effective transmission-blocking interventions. Primaquine, the only WHO recommended transmission-blocking drug, is not extensively utilized because of the toxicity issues in G6PD deficient individuals.

Improving Methods for Analyzing Antimalarial Drug Efficacy Trials: Molecular Correction Based on Length-Polymorphic Markers msp-1, msp-2, and glurp

September 9, 2019 - 16:25 -- Open Access
Author(s): 
S. Jones, K. Kay, E. M. Hodel, S. Chy, A. Mbituyumuremyi, A. Uwimana, D. Menard, I. Felger and I. Hastings
Reference: 
Antimicrob. Agents Chemother. August 2019 63:e00590-19

Drug efficacy trials monitor the continued efficacy of front-line drugs against falciparum malaria.

NOT Open Access | Dihydroartemisinin, an antimalarial drug, induces absent in melanoma 2 inflammasome activation and autophagy in human hepatocellular carcinoma HepG2215 cells

June 3, 2019 - 15:24 -- NOT Open Access
Author(s): 
Xinli Shi, Li Wang, Laifeng Ren, Jianchun Li, Shenghao Li, Qingzhuo Cui, Sheng Li
Reference: 
Phytotherapy Research, Volume33, Issue5 May 2019 Pages 1413-1425

As an effective antimalarial drug, Dihydroartemisinin (DHA) is readily isolated from the traditional Chinese medicine of Artemisia annua.

The past, present and future of anti-malarial medicines

March 26, 2019 - 15:56 -- Open Access
Author(s): 
Edwin G. Tse, Marat Korsik and Matthew H. Todd
Reference: 
Malaria Journal 2019 18:93, 22 March 2019

Great progress has been made in recent years to reduce the high level of suffering caused by malaria worldwide.

NOT Open Access | Fixed dose combinations of anti‐tubercular, antimalarial and antiretroviral medicines on the Indian market: critical analysis of ubiquity, sales and regulatory status

February 6, 2019 - 15:40 -- NOT Open Access
Author(s): 
Virendra S. Ligade, Tanmay M. Thakar, Swapnil J. Dengale
Reference: 
Tropical Medicine & International Health Volume24, Issue2 February 2019 Pages 238-246

A large proportion of FDC formulations available in India has never been approved by CDSCO, hence raising the doubts about their safety and efficacy.

NOT Open Access | Synthesis, antimalarial activities and cytotoxicities of amino-artemisinin-1,2-disubstituted ferrocene hybrids

October 2, 2018 - 16:46 -- NOT Open Access
Author(s): 
Christo de Lange, Dina Coertzen, Frans J. Smit, Johannes F. Wentzel, Ho Ning Wong, Lyn-Marie Birkholtz, Richard K. Haynes, David D. N'Da
Reference: 
Bioorganic & Medicinal Chemistry Letters Volume 28, Issue 19, 15 October 2018, Pages 3161-3163

Artemisinin-ferrocene conjugates incorporating a 1,2-disubstituted ferrocene analogous to that embedded in ferroquine but attached via a piperazine linker to C10 of the artemisinin were prepared from the piperazine artemisinin derivative, and activities were evaluated against asexual blood stages of chloroquine (CQ) sensitive NF54 and CQ resistant K1 and W2 strains of Plasmodium falciparum (Pf).

NOT Open Access | Artemisone and Artemiside Are Potent Panreactive Antimalarial Agents That Also Synergize Redox Imbalance in Plasmodium falciparum Transmissible Gametocyte Stages

August 1, 2018 - 14:39 -- NOT Open Access
Author(s): 
Dina Coertzen, Janette Reader, Richard K. Haynes, et al.
Reference: 
Antimicrob. Agents Chemother. August 2018 vol. 62 no. 8 e02214-17

The emergence of resistance toward artemisinin combination therapies (ACTs) by the malaria parasite Plasmodium falciparum has the potential to severely compromise malaria control.

How long do rapid diagnostic tests remain positive after anti-malarial treatment?

June 13, 2018 - 08:29 -- Open Access
Author(s): 
Ursula Dalrymple, Rohan Arambepola, Peter W. Gething and Ewan Cameron
Reference: 
Malaria Journal 2018 17:228, 8 June 2018

RDTs remain positive for a highly variable amount of time after treatment with anti-malarials, and the duration of positivity is highly dependent on the type of RDT used for diagnosis.

Medical Treatment: 

Pages

Subscribe to RSS - antimalarials